ClinicalTrials.gg
CompletedNCT01189500Updated Nov 7, 2011Results posted

Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

A Phase 4 interventional study of Tamoxifen and Tamoxifen and Desvenlafaxine Succinate Sustained Release in Pharmacokinetics, sponsored by Pfizer. Completed at 2 sites in United States. Open to female participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-07.

Sponsored by Pfizer · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
45 Years and older
Sex
Female
01

Study summary

The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine SR on the pharmacokinetics of Tamoxifen and endoxifen when coadministered to healthy post-menopausal female subjects. This study will also evaluate the safety and tolerability of Desvenlafaxine SR and Tamoxifen when coadministered to healthy post-menopausal female subjects.

02

Conditions studied

  • Pharmacokinetics

Keywords

  • Pharmacokinetic
  • safety and tolerability
  • genetic testing
  • CYP 2D6
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female subjects, at least 45 years of age, with confirmed post-menopausal status
  • Hysterectomized subjects
  • (BMI) less than or equal to 34.0 kg/m2
  • Nonsmoker or smoker of fewer than 5 cigarettes per day as determined by history
  • An document signed and dated by the subject

Exclusion criteria

Exclusion Criteria:

  • History of significant blood, kidney, endocrine, lung, gastrointestinal, heart, liver, psychiatric, neurologic, or allergic disease
  • Presence or history of deep vein thrombosis or
  • History of seizure disorder
  • Presence or history of glaucoma or increased intraocular pressure
  • Allergy to or unable to tolerate tamoxifen, desvenlafaxine, or venlafaxine
  • History of substance abuse within 1 year of study
  • A positive urine drug screen
  • Treatment with an drug within 30 days
  • Consumption of grapefruit or grapefruit related citrus fruits
  • 12 lead demonstrating >450 msec at screening
  • Pregnant or nursing females
  • Use of prescription or nonprescription drugs and dietary supplements
  • History of sensitivity to heparin or heparin induced thrombocytopenia
  • Severe acute or chronic medical or psychiatric condition or laboratory abnormality
  • Use of CYP 2D6 inhibitors and CYP 3A4 inhibitors/inducers
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Tamoxifen and Desvenlafaxine SR

    Drug: Tamoxifen · Drug: Tamoxifen and Desvenlafaxine Succinate Sustained Release

Interventions

  • Period 1-Tamoxifen 40mg on study day 1.

  • DrugTamoxifen and Desvenlafaxine Succinate Sustained Release

    Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.

06

What researchers measure

Primary outcomes

  1. Tamoxifen Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR

    Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞); measured as nanograms multiplied by hours divided by milliliters (ng\*hr/mL).

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  2. Endoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Endoxifen Alone and When Coadministered With DVS SR

    Endoxifen is a metabolite of Tamoxifen. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

Secondary outcomes

  1. Tamoxifen Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR

    Cmax measured as nanograms per milliliters (ng/mL).

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  2. Tamoxifen Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR

    Time for maximum observed plasma concentration.

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  3. Tamoxifen Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR

    Terminal half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  4. Tamoxifen Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  5. Tamoxifen Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR

    Calculated as Dose / (AUCinf \* kel); where kel=terminal phase rate constant.

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  6. Endoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  7. Endoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR

    Time for maximum observed plasma concentration.

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  8. Endoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR

    Terminal half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  9. Endoxifen (Metabolite) Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  10. Endoxifen (Metabolite) Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  11. N-desmethyl-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR

    N-desmethyl-tamoxifen is a metabolite of Tamoxifen. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  12. N-desmethyl-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  13. N-desmethyl-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR

    Time for maximum observed plasma concentration.

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  14. N-desmethyl-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR

    Terminal half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  15. N-desmethyl-tamoxifen (Metabolite) Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  16. N-desmethyl-tamoxifen (Metabolite) Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  17. 4-hydroxy-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR

    4-hydroxy-tamoxifen is a metabolite of Tamoxifen. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  18. 4-hydroxy-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  19. 4-hydroxy-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR

    Time for maximum observed plasma concentration.

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  20. 4-hydroxy-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR

    Terminal half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  21. 4-hydroxy-tamoxifen (Metabolite) Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  22. 4-hydroxy-tamoxifen (Metabolite) Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR

    Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.

  23. Plasma Tamoxifen Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR

    Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.250 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.

    Time frame: Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing

  24. Plasma Endoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR

    Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.

    Time frame: Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing

  25. Plasma N-desmethyl-tamoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR

    Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.250 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.

    Time frame: Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing

  26. Plasma 4-hydroxy-tamoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR

    Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.

    Time frame: Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing

07

Results

Posted Oct 17, 2011

Participant flow

Period 1: TAMOX Alone
Participant flow — Period 1: TAMOX Alone
MilestoneTamoxifen 40 mg, Tamoxifen 40 mg + DVS SR 100 mg
Started30
Completed29
Not completed1
Withdrew: Adverse event1
Period 2: Coadministration TAMOX+DVS SR
Participant flow — Period 2: Coadministration TAMOX+DVS SR
MilestoneTamoxifen 40 mg, Tamoxifen 40 mg + DVS SR 100 mg
Started29
Completed28
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryTamoxifen Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR

Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞); measured as nanograms multiplied by hours divided by milliliters (ng\*hr/mL).

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · ng*hr/mL
Tamoxifen Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR
ng*hr/mLTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
Tamoxifen Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR5751 ± 1540.15888 ± 1905.5
Statistical analysis
  • Tamoxifen 40 mg (Period 1) vs Tamoxifen 40 mg + DVS SR 100 mg (Period 2) · Ratio of adjusted means: 100.69 · 90% CI 96.70 to 104.85Values have been back-transformed from the log scale.
PrimaryEndoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Endoxifen Alone and When Coadministered With DVS SR

Endoxifen is a metabolite of Tamoxifen. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · ng*hr/mL
Endoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Endoxifen Alone and When Coadministered With DVS SR
ng*hr/mLTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
Endoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Endoxifen Alone and When Coadministered With DVS SR677.7 ± 200.42505.6 ± 220.87
SecondaryTamoxifen Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR

Cmax measured as nanograms per milliliters (ng/mL).

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · ng/mL
Tamoxifen Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
ng/mLTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
Tamoxifen Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR70.58 ± 16.31070.33 ± 14.484
Statistical analysis
  • Tamoxifen 40 mg (Period 1) vs Tamoxifen 40 mg + DVS SR 100 mg (Period 2) · Ratio of adjusted means: 99.44 · 90% CI 94.02 to 105.17Values have been back-transformed from the log scale.
SecondaryTamoxifen Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR

Time for maximum observed plasma concentration.

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Median · hours
Tamoxifen Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR
hoursTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
Tamoxifen Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR4.00 (3.00 to 8.00)4.00 (3.00 to 8.00)
SecondaryTamoxifen Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR

Terminal half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Mean · hours
Tamoxifen Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR
hoursTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
Tamoxifen Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR250.5 ± 44.410242.3 ± 51.851
SecondaryTamoxifen Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · mL/min
Tamoxifen Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR
mL/minTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
Tamoxifen Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR115.9 ± 34.544113.2 ± 44.545
SecondaryTamoxifen Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR

Calculated as Dose / (AUCinf \* kel); where kel=terminal phase rate constant.

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · liters
Tamoxifen Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR
litersTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
Tamoxifen Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR2474 ± 461.712321 ± 419.76
SecondaryEndoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · ng/mL
Endoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
ng/mLTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
Endoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR1.077 ± 0.45281.226 ± 0.4956
Statistical analysis
  • Tamoxifen 40 mg (Period 1) vs Tamoxifen 40 mg + DVS SR 100 mg (Period 2) · Ratio of adjusted means: 92.04 · 90% CI 84.71 to 100.00Values have been back-transformed from the log scale.
SecondaryEndoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR

Time for maximum observed plasma concentration.

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Median · hours
Endoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR
hoursTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
Endoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR216 (47.9 to 312)120 (47.9 to 384)
SecondaryEndoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR

Terminal half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Mean · hours
Endoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR
hoursTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
Endoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR207.5 ± 43.59232.5 ± 56.719
SecondaryEndoxifen (Metabolite) Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · mL/min

No measurements were reported for this outcome.

SecondaryEndoxifen (Metabolite) Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR
Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · liters

No measurements were reported for this outcome.

SecondaryN-desmethyl-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR

N-desmethyl-tamoxifen is a metabolite of Tamoxifen. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · ng*hr/mL
N-desmethyl-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR
ng*hr/mLTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
N-desmethyl-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR8187 ± 1688.09329 ± 2236.8
SecondaryN-desmethyl-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · ng/mL
N-desmethyl-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
ng/mLTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
N-desmethyl-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR18.30 ± 3.757624.42 ± 4.3709
Statistical analysis
  • Tamoxifen 40 mg (Period 1) vs Tamoxifen 40 mg + DVS SR 100 mg (Period 2) · Ratio of adjusted means: 112.07 · 90% CI 107.44 to 116.90Values have been back-transformed from the log scale.
SecondaryN-desmethyl-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR

Time for maximum observed plasma concentration.

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Median · hours
N-desmethyl-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR
hoursTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
N-desmethyl-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR35.9 (4.00 to 312)47.9 (4.00 to 168)
SecondaryN-desmethyl-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR

Terminal half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Mean · hours
N-desmethyl-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR
hoursTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
N-desmethyl-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR256.0 ± 24.042265.6 ± 32.082
SecondaryN-desmethyl-tamoxifen (Metabolite) Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · mL/min

No measurements were reported for this outcome.

SecondaryN-desmethyl-tamoxifen (Metabolite) Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR
Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · liters

No measurements were reported for this outcome.

Secondary4-hydroxy-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR

4-hydroxy-tamoxifen is a metabolite of Tamoxifen. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · ng*hr/mL
4-hydroxy-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR
ng*hr/mLTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
4-hydroxy-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR117.5 ± 55.433133.9 ± 62.784
Statistical analysis
  • Tamoxifen 40 mg (Period 1) vs Tamoxifen 40 mg + DVS SR 100 mg (Period 2) · Ratio of adjusted means: 105.60 · 90% CI 99.74 to 111.81Values have been back-transformed from the log scale.
Secondary4-hydroxy-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · ng/mL
4-hydroxy-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
ng/mLTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
4-hydroxy-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR0.6716 ± 0.16490.7247 ± 0.1799
Statistical analysis
  • Tamoxifen 40 mg (Period 1) vs Tamoxifen 40 mg + DVS SR 100 mg (Period 2) · Ratio of adjusted means: 108.47 · 90% CI 103.51 to 113.67Values have been back-transformed from the log scale.
Secondary4-hydroxy-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR

Time for maximum observed plasma concentration.

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Median · hours
4-hydroxy-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR
hoursTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
4-hydroxy-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR6.00 (4.00 to 12.00)6.00 (3.00 to 23.9)
Secondary4-hydroxy-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR

Terminal half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Mean · hours
4-hydroxy-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR
hoursTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
4-hydroxy-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR165.2 ± 49.699177.0 ± 54.525
Secondary4-hydroxy-tamoxifen (Metabolite) Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).

Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · mL/min

No measurements were reported for this outcome.

Secondary4-hydroxy-tamoxifen (Metabolite) Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR
Time frame:
Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Reported as:
Geometric mean · liters

No measurements were reported for this outcome.

SecondaryPlasma Tamoxifen Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR

Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.250 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.

Time frame:
Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing
Reported as:
Median · ng/mL
Plasma Tamoxifen Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR
ng/mLTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
0 hourNA (NA to NA)1.300 (0.293 to 4.66)
0.5 hour post dose1.875 (0.000 to 10.3)4.650 (1.70 to 19.1)
1 hour post dose11.45 (0.769 to 36.1)13.90 (3.31 to 47.8)
2 hours post dose37.20 (2.55 to 74.7)33.60 (11.0 to 75.2)
3 hours post dose54.50 (6.57 to 100)55.60 (17.0 to 99.4)
4 hours post dose68.25 (26.9 to 95.7)72.20 (26.6 to 90.7)
6 hours post dose58.95 (40.1 to 89.3)60.90 (38.5 to 90.8)
8 hours post dose54.75 (32.2 to 77.8)56.10 (33.6 to 73.9)
12 hours post dose40.40 (21.5 to 61.0)35.30 (22.8 to 51.7)
16 hours post dose27.30 (16.4 to 41.6)26.20 (12.9 to 39.5)
24 hours post dose24.50 (16.9 to 30.9)25.50 (12.0 to 39.3)
48 hours post dose15.40 (7.86 to 22.1)16.20 (8.36 to 27.1)
72 hours post dose12.55 (7.28 to 18.8)12.60 (7.50 to 27.7)
120 hours post dose10.55 (4.78 to 16.3)11.60 (5.85 to 21.0)
168 hours post dose9.120 (3.75 to 13.2)9.930 (4.83 to 14.9)
216 hours post dose7.555 (4.10 to 14.0)8.150 (3.32 to 17.9)
264 hours post dose7.575 (3.25 to 12.0)7.270 (2.75 to 13.5)
312 hours post dose6.445 (2.58 to 12.7)6.920 (2.85 to 14.3)
384 hours post dose5.180 (2.18 to 10.4)5.600 (1.83 to 12.7)
456 hours post dose4.300 (1.65 to 8.75)4.330 (1.65 to 9.13)
528 hours post dose3.560 (1.39 to 8.14)4.160 (1.03 to 10.9)
SecondaryPlasma Endoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR

Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.

Time frame:
Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing
Reported as:
Median · ng/mL
Plasma Endoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR
ng/mLTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
0 hourNA (NA to NA)0.2900 (0.000 to 0.799)
0.5 hour post doseNA (NA to NA)0.3370 (0.000 to 0.792)
1 hour post doseNA (NA to NA)0.3430 (0.000 to 1.03)
2 hours post dose0.0000 (0.000 to 0.126)0.4100 (0.102 to 1.15)
3 hours post dose0.0000 (0.000 to 0.275)0.5020 (0.000 to 1.14)
4 hours post dose0.1760 (0.000 to 0.590)0.6350 (0.119 to 1.26)
6 hours post dose0.2485 (0.000 to 0.516)0.5870 (0.000 to 1.00)
8 hours post dose0.2895 (0.102 to 0.624)0.7310 (0.149 to 1.39)
12 hours post dose0.4470 (0.116 to 0.884)0.7310 (0.146 to 1.39)
16 hours post dose0.4330 (0.111 to 0.818)0.7130 (0.120 to 1.46)
24 hours post dose0.6215 (0.162 to 1.05)0.9900 (0.203 to 1.47)
48 hours post dose0.9065 (0.150 to 1.40)1.180 (0.270 to 2.12)
72 hours post dose0.9740 (0.178 to 1.54)1.180 (0.208 to 1.83)
120 hours post dose1.095 (0.135 to 1.89)1.240 (0.287 to 2.13)
168 hours post dose1.120 (0.128 to 1.97)1.140 (0.169 to 2.23)
216 hours post dose1.120 (0.149 to 1.78)1.080 (0.193 to 1.80)
264 hours post dose1.145 (0.166 to 1.57)1.160 (0.168 to 1.94)
312 hours post dose1.035 (0.148 to 1.69)0.9760 (0.157 to 1.86)
384 hours post dose0.8560 (0.169 to 1.50)0.9470 (0.121 to 1.61)
456 hours post dose0.7060 (0.104 to 1.51)0.9150 (0.119 to 1.37)
528 hours post dose0.6210 (0.000 to 1.23)0.7040 (0.000 to 1.47)
SecondaryPlasma N-desmethyl-tamoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR

Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.250 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.

Time frame:
Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing
Reported as:
Median · ng/mL
Plasma N-desmethyl-tamoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR
ng/mLTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
0 hourNA (NA to NA)3.600 (1.22 to 8.84)
0.5 hour post dose0.0000 (0.000 to 0.465)4.120 (1.97 to 11.2)
1 hour post dose0.8050 (0.000 to 3.34)5.650 (2.64 to 12.4)
2 hours post dose4.210 (0.310 to 9.46)9.770 (4.51 to 16.7)
3 hours post dose9.440 (1.03 to 20.2)14.80 (6.30 to 26.4)
4 hours post dose12.55 (2.67 to 20.7)18.70 (9.09 to 29.9)
6 hours post dose14.10 (7.61 to 23.3)19.30 (11.8 to 26.1)
8 hours post dose14.90 (9.97 to 23.5)20.40 (14.3 to 30.3)
12 hours post dose16.10 (10.8 to 26.8)19.00 (11.1 to 25.7)
16 hours post dose14.55 (9.14 to 20.1)18.40 (11.6 to 35.1)
24 hours post dose16.90 (8.64 to 23.3)21.90 (12.7 to 32.4)
48 hours post dose16.45 (9.49 to 23.3)24.00 (13.3 to 34.9)
72 hours post dose16.45 (8.01 to 21.8)19.80 (13.9 to 31.5)
120 hours post dose15.10 (8.26 to 22.9)19.80 (15.0 to 31.4)
168 hours post dose14.40 (8.04 to 26.1)16.80 (12.7 to 26.3)
216 hours post dose13.50 (7.75 to 19.6)15.60 (8.60 to 24.3)
264 hours post dose12.65 (8.13 to 17.6)15.40 (5.80 to 22.5)
312 hours post dose11.40 (6.99 to 18.0)14.40 (8.39 to 20.6)
384 hours post dose10.15 (6.46 to 15.5)13.10 (6.86 to 19.7)
456 hours post dose8.730 (5.35 to 14.2)10.50 (3.24 to 16.3)
528 hours post dose8.730 (4.69 to 13.0)10.40 (4.36 to 21.7)
SecondaryPlasma 4-hydroxy-tamoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR

Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.

Time frame:
Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing
Reported as:
Median · ng/mL
Plasma 4-hydroxy-tamoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR
ng/mLTamoxifen 40 mg (Period 1)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
0 hourNA (NA to NA)0.0000 (0.000 to 0.130)
0.5 hour post doseNA (NA to NA)0.0000 (0.000 to 0.171)
1 hour post doseNA (NA to NA)0.0000 (0.000 to 0.321)
2 hours post dose0.2060 (0.000 to 0.431)0.2030 (0.000 to 0.633)
3 hours post dose0.4335 (0.000 to 0.811)0.3960 (0.136 to 1.00)
4 hours post dose0.5900 (0.101 to 1.03)0.6420 (0.232 to 1.13)
6 hours post dose0.6145 (0.346 to 0.889)0.7060 (0.340 to 0.985)
8 hours post dose0.6290 (0.307 to 0.985)0.7100 (0.408 to 1.06)
12 hours post dose0.5910 (0.312 to 0.966)0.5860 (0.354 to 1.07)
16 hours post dose0.4920 (0.322 to 0.887)0.5640 (0.308 to 0.947)
24 hours post dose0.5395 (0.329 to 0.930)0.5780 (0.300 to 1.02)
48 hours post dose0.4925 (0.233 to 0.931)0.4910 (0.235 to 1.12)
72 hours post dose0.3795 (0.174 to 0.717)0.4010 (0.200 to 0.903)
120 hours post dose0.2845 (0.102 to 0.627)0.2920 (0.171 to 0.745)
168 hours post dose0.2180 (0.000 to 0.525)0.2270 (0.107 to 0.548)
216 hours post dose0.1840 (0.000 to 0.435)0.1870 (0.000 to 0.423)
264 hours post dose0.1590 (0.000 to 0.361)0.1600 (0.000 to 0.367)
312 hours post dose0.1315 (0.000 to 0.338)0.1380 (0.000 to 0.323)
384 hours post dose0.1125 (0.000 to 0.280)0.1180 (0.000 to 0.286)
456 hours post dose0.0000 (0.000 to 0.283)0.0000 (0.000 to 0.208)
528 hours post dose0.0000 (0.000 to 0.230)0.0000 (0.000 to 0.296)

Adverse events

Collected over Baseline up to Day 36 (follow-up telephone visit). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tamoxifen 40 mg (Period 1)—1/30 (3.3%)11/30 (36.7%)
DVS SR 100 mg (Period 2)—0/29 (0%)17/29 (58.6%)
Tamoxifen 40 mg + DVS SR 100 mg (Period 2)—0/29 (0%)24/29 (82.8%)
Most frequent serious events
Most frequent serious events
EventTamoxifen 40 mg (Period 1)DVS SR 100 mg (Period 2)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
CholecystitisHepatobiliary disorders1/300/290/29
CholelithiasisHepatobiliary disorders1/300/290/29
Most frequent other events
Showing 10 of 43
Most frequent other events
EventTamoxifen 40 mg (Period 1)DVS SR 100 mg (Period 2)Tamoxifen 40 mg + DVS SR 100 mg (Period 2)
HeadacheNervous system disorders1/301/299/29
InsomniaPsychiatric disorders0/302/298/29
PalpitationsCardiac disorders0/300/297/29
ConstipationGastrointestinal disorders2/306/293/29
NauseaGastrointestinal disorders0/304/292/29
Upper respiratory tract infectionInfections and infestations0/300/294/29
Abdominal painGastrointestinal disorders0/300/293/29
Dry mouthGastrointestinal disorders0/301/293/29
DyspepsiaGastrointestinal disorders0/302/293/29
ToothacheGastrointestinal disorders0/300/293/29

Baseline characteristics

Age, Customized
Age, Customized(participants)Tamoxifen 40 mg, Tamoxifen 40 mg + DVS SR 100 mg
45 to 64 years27
≥65 years3
Sex/Gender, Customized
Sex/Gender, Customized(participants)Tamoxifen 40 mg, Tamoxifen 40 mg + DVS SR 100 mg
Number30
08

Study locations

2 sites
  • Pfizer Investigational Site
    Miami, Florida 33126, United States
  • Pfizer Investigational Site
    Miami, Florida 33134, United States
09

References and documents

Publications

  • Nichols AI, Lubaczewski S, Liang Y, Matschke K, Braley G, Ramey T. Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects. Int J Clin Pharmacol Ther. 2014 Oct;52(10):830-41. doi: 10.5414/CP201958. PubMed 25138680 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2010
First posted
Aug 26, 2010
Start
Aug 2010
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Oct 17, 2011
Last update
Nov 7, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01189500
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 26, 2010
Start date
Aug 2010
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Oct 17, 2011
Last update
Nov 7, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamoxifen

Start the discussion